Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985

Wendy L. Nelson, Frederick (Fritz) Fraunfelder, Judith M. Sills, Janet B. Arrowsmith, Joel N. Kuritsky

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

Between September 1978 and December 1985, 450 case reports of serious respiratory and cardiovascular events and 32 case reports of death attributed to ophthalmic timolol were received by the United States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side Effects. Two hundred sixty-seven patients (55%) experienced a cardiac arrhythmia or a bronchospasm-related event. The median age was 68 years (n = 365). Fifty-five percent of the patients were women and 45% were men (n = 41). Of the 212 persons for whom medical history was provided, 129 (61%) had respiratory disease, 65 (31%) had cardiovascular disease, 13 (6%) had other illnesses, and five (2%) had no underlying illness. Of the 318 patients for whom data on duration of drug use were available 106 (33%) experienced their adverse event within one week of beginning timolol therapy: 73 (23%) had their events on the first day of therapy. Of 192 patients for whom information was available 177 (92%) improved after the drug was discontinued.

Original languageEnglish (US)
Pages (from-to)606-611
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume102
Issue number5
StatePublished - Nov 15 1986

Fingerprint

Timolol
Ophthalmic Solutions
Pharmaceutical Preparations
Bronchial Spasm
United States Food and Drug Administration
Registries
Cardiac Arrhythmias
Cardiovascular Diseases
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. / Nelson, Wendy L.; Fraunfelder, Frederick (Fritz); Sills, Judith M.; Arrowsmith, Janet B.; Kuritsky, Joel N.

In: American Journal of Ophthalmology, Vol. 102, No. 5, 15.11.1986, p. 606-611.

Research output: Contribution to journalArticle

Nelson, Wendy L. ; Fraunfelder, Frederick (Fritz) ; Sills, Judith M. ; Arrowsmith, Janet B. ; Kuritsky, Joel N. / Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. In: American Journal of Ophthalmology. 1986 ; Vol. 102, No. 5. pp. 606-611.
@article{b98a36c8f7554e3ea82337e0b181d657,
title = "Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985",
abstract = "Between September 1978 and December 1985, 450 case reports of serious respiratory and cardiovascular events and 32 case reports of death attributed to ophthalmic timolol were received by the United States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side Effects. Two hundred sixty-seven patients (55{\%}) experienced a cardiac arrhythmia or a bronchospasm-related event. The median age was 68 years (n = 365). Fifty-five percent of the patients were women and 45{\%} were men (n = 41). Of the 212 persons for whom medical history was provided, 129 (61{\%}) had respiratory disease, 65 (31{\%}) had cardiovascular disease, 13 (6{\%}) had other illnesses, and five (2{\%}) had no underlying illness. Of the 318 patients for whom data on duration of drug use were available 106 (33{\%}) experienced their adverse event within one week of beginning timolol therapy: 73 (23{\%}) had their events on the first day of therapy. Of 192 patients for whom information was available 177 (92{\%}) improved after the drug was discontinued.",
author = "Nelson, {Wendy L.} and Fraunfelder, {Frederick (Fritz)} and Sills, {Judith M.} and Arrowsmith, {Janet B.} and Kuritsky, {Joel N.}",
year = "1986",
month = "11",
day = "15",
language = "English (US)",
volume = "102",
pages = "606--611",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985

AU - Nelson, Wendy L.

AU - Fraunfelder, Frederick (Fritz)

AU - Sills, Judith M.

AU - Arrowsmith, Janet B.

AU - Kuritsky, Joel N.

PY - 1986/11/15

Y1 - 1986/11/15

N2 - Between September 1978 and December 1985, 450 case reports of serious respiratory and cardiovascular events and 32 case reports of death attributed to ophthalmic timolol were received by the United States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side Effects. Two hundred sixty-seven patients (55%) experienced a cardiac arrhythmia or a bronchospasm-related event. The median age was 68 years (n = 365). Fifty-five percent of the patients were women and 45% were men (n = 41). Of the 212 persons for whom medical history was provided, 129 (61%) had respiratory disease, 65 (31%) had cardiovascular disease, 13 (6%) had other illnesses, and five (2%) had no underlying illness. Of the 318 patients for whom data on duration of drug use were available 106 (33%) experienced their adverse event within one week of beginning timolol therapy: 73 (23%) had their events on the first day of therapy. Of 192 patients for whom information was available 177 (92%) improved after the drug was discontinued.

AB - Between September 1978 and December 1985, 450 case reports of serious respiratory and cardiovascular events and 32 case reports of death attributed to ophthalmic timolol were received by the United States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side Effects. Two hundred sixty-seven patients (55%) experienced a cardiac arrhythmia or a bronchospasm-related event. The median age was 68 years (n = 365). Fifty-five percent of the patients were women and 45% were men (n = 41). Of the 212 persons for whom medical history was provided, 129 (61%) had respiratory disease, 65 (31%) had cardiovascular disease, 13 (6%) had other illnesses, and five (2%) had no underlying illness. Of the 318 patients for whom data on duration of drug use were available 106 (33%) experienced their adverse event within one week of beginning timolol therapy: 73 (23%) had their events on the first day of therapy. Of 192 patients for whom information was available 177 (92%) improved after the drug was discontinued.

UR - http://www.scopus.com/inward/record.url?scp=0023009494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023009494&partnerID=8YFLogxK

M3 - Article

C2 - 3777080

AN - SCOPUS:0023009494

VL - 102

SP - 606

EP - 611

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -